OrbusNeich Medical's P/E ratio aligns with other firms despite limited growth expectations, hinting at potential investor oversight. The company's future prospects based on the P/E ratio alone are not promising, as the predicted future earnings are unlikely to support a more positive sentiment for long.
Despite increased capital investment, the company's ROCE has remained flat, suggesting a lack of high return investments. A 61% stock price drop over the last year indicates investor skepticism about growth prospects.
HopelessChi
:
heavily punished since 2020 clampdown. this was the cause of the powerful clan and the impact is now more than 3 years. this market entirely had lost investors
An exchange-traded fund designed to track the price performance of Bitcoin or other major crypto, allowing investors to participate in the market without directly purchasing the assets.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in HK Crypto ETF, ranked from highest to lowest based on real-time market data. An exchange-traded fund designed to track the price performance of Bitcoin or other major crypto, allowing investors to participate in the market without directly purchasing the assets.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in HK Crypto ETF, ranked from highest to lowest based on real-time market data.
ORBUSNEICH Stock Forum
Active Heavyweights:
$MEITUAN-W (03690.HK)$ closed at $90.45, down 12.2%
$BABA-W (09988.HK)$ closed at $72.7, down 2.2%
$HKEX (00388.HK)$ closed at $279.6, do...
No comment yet